Kyverna Therapeutics, Inc. Common Stock (KYTX) Live Share Price, Invest From India

Kyverna Therapeutics, Inc. Common Stock Stock Performance

as on April 17, 2026 at 6:59 am IST

Day's Low
Day's High
$9.17
Day's Price Range
$9.58
$9.54
3.88%
Downside
0.42%
Upside
52 Week's Low
52 Week's High
$1.78
52-Week Price Range
$13.67
$9.54
81.34%
Downside
43.29%
Upside

Kyverna Therapeutics, Inc. Common Stock share price movements today

Previous Close: $9.40
Open: $9.40
Volume: 557.7K
Day's Low - High: $9.17 - $9.58
52 Week Low - High: $1.78 - $13.67

Kyverna Therapeutics, Inc. Common Stock Historical Returns

1 Month Return: + 8.3 %
3 Month Return: + 14 %
1 Year Return: + 412.37 %
3 Year Return: 0 %
5 Year Return: 0 %

Kyverna Therapeutics, Inc. Common Stock Stock Fundamentals & Key Indicators

Check Kyverna Therapeutics, Inc. Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$576.9M

EPS (TTM)

-2.9245

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-168.0M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-64.67%

Kyverna Therapeutics, Inc. Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kyverna Therapeutics, Inc. Common Stock with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Kyverna Therapeutics, Inc. Common Stock	BUY	$576.9M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$42.7B	130.51%	136.81	8.45%
Vertex Pharmaceuticals Inc	BUY	$110.8B	98.57%	28.42	32.94%
BeiGene, Ltd.	NA	$36.8B	NA	129.84	5.37%
Regeneron Pharmaceuticals Inc	BUY	$78.9B	48.43%	17.98	31.41%

Stock Returns calculator for Kyverna Therapeutics, Inc. Common Stock Stock including INR - Dollar returns

The Kyverna Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Kyverna Therapeutics, Inc. Common Stock investment value today

Current value as on today

₹5,58,880

Returns

₹4,58,880

(+458.88%)

Returns from Kyverna Therapeutics, Inc. Common Stock Stock

₹4,12,903 (+412.9%)

Dollar Impact

₹45,977 (+45.98%)

Analyst Recommendation on Kyverna Therapeutics, Inc. Common Stock Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Kyverna Therapeutics, Inc. Common Stock. Average target price of $29.6

Kyverna Therapeutics, Inc. Common Stock Share Price Target

Get share price movements and forecasts by analysts on Kyverna Therapeutics, Inc. Common Stock.

What analysts predicted

67.77%UPSIDE

Target Price

$29.6

Current Price

$9.54

Analyzed by

10 Analysts

Target

$29.60

Kyverna Therapeutics, Inc. Common Stock target price $29.6, a slight upside of 67.77% compared to current price of $9.54. According to 10 analysts rating.

Kyverna Therapeutics, Inc. Common Stock Stock’s Investor Sentiment and Interest

Search interest for Kyverna Therapeutics, Inc. Common Stock Stock has decreased by -79% in the last 30 days, reflecting a downward trend in search activity.

Time period: March 18, 2026 to April 17, 2026

Change:-79% versus previous 30 day period

Kyverna Therapeutics, Inc. Common Stock Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-	-	-	-	2	-	-	-	-
Gross Profit	0	-17	0	0	-29	0	0	0	0	0
Operating Income	-16	-21	0	-33	-38	-41	-47	-44	-38	-39
EBITDA	-14	-21	0	-28	-36	-36	-44	-41	-36	-38
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-15	-20	0	-28	-34	-37	-44	-42	-36	-37
Income Tax Expense	-	0	0	-	-	-	-	-	-	-
Net Income	-15	-20	0	-28	-34	-37	-44	-42	-36	-37
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-1852.22%	0.00%	0.00%	0.00%	0.00%

Kyverna Therapeutics, Inc. Common Stock Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	5	7	-	-	-
Gross Profit	5	7	-1	-2	-1
Operating Income	-26	-29	-62	-142	-169
EBITDA	-25	-27	-58	-125	-167
Interest Expense	0	0	0	0	0
Depreciation	0	1	1	2	1
Income Before Tax	-26	-28	-60	-127	-161
Income Tax Expense	0	0	0	-127	-
Net Income	-26	-28	-60	-127	-161
Net Profit Margin	-465.88%	-411.29%	0.00%	0.00%	0.00%

Kyverna Therapeutics, Inc. Common Stock Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-20	-26	-28	-34	-37	-44	-42	-36	-37
Operating Cash Flow	-18	-25	-24	-27	-37	-44	-31	-43	-33
Investing Cash Flow	31	-122	-67	0	29	5	29	22	-17
Financing Cash Flow	-1	338	0	0	0	0	0	1	140
Change in Cash	11	189	-92	-26	-8	-39	-3	-19	89

Kyverna Therapeutics, Inc. Common Stock Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-28	-60	-127	-161
Operating Cash Flow	-36	-52	-114	-153
Investing Cash Flow	-14	-8	-160	40
Financing Cash Flow	11	58	337	141
Change in Cash	-38	-3	61	27

Insights on Kyverna Therapeutics, Inc. Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, KYTX has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 1 year, KYTX stock has moved up by 405.4%

About Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Organisation	Kyverna Therapeutics, Inc. Common Stock
Headquarters	5980 Horton Street, Emeryville, CA, United States, 94608
Industry	Biotechnology
CEO	Mr. Warner Biddle
E-voting on shares	Click here to vote

Key Management of Kyverna Therapeutics, Inc. Common Stock

Name	Title
Dr. Marc Grasso M.D.	Chief Financial Officer
Dr. Naji H. Gehchan M.B.A., M.D.	Chief Medical & Development Officer
Ms. Tracy Rossin	Senior Vice President of Corporate Affairs & Communications and Investor Relations
Ms. Cara Bauer Ph.D.	Chief Human Resources Officer
Mr. Dan Maziasz	Chief Business Officer
Ms. Christi L. Shaw	Executive Chairperson
Mr. Warner Biddle	CEO & Director
Dr. Tom Van Blarcom Ph.D.	Senior VP & Head of Research
Mr. Mayo Pujols	Chief Technology Officer
Ms. Jessica Serra	Head of Investor Relations

FAQs

What is Kyverna Therapeutics, Inc. Common Stock share price today?

Kyverna Therapeutics, Inc. Common Stock share price today is $9.54 as on April 17, 2026 at 1:29 am IST at the close of the market. Kyverna Therapeutics, Inc. Common Stock share today touched a day high of $9.58 and a low of $9.17.

What is the 52 week high and 52 week low for Kyverna Therapeutics, Inc. Common Stock share?

Kyverna Therapeutics, Inc. Common Stock share touched a 52 week high of $13.67 on December 15, 2025 and a 52 week low of $1.78 on April 17, 2025. Kyverna Therapeutics, Inc. Common Stock stock price today i.e. April 17, 2026 at 1:29 am IST is closed at $9.54,which is 30.21% down from its 52 week high and 435.96% up from its 52 week low.

What is Kyverna Therapeutics, Inc. Common Stock's market capitalisation today?

Kyverna Therapeutics, Inc. Common Stock market capitalisation is $0.00T as on April 17, 2026 at 1:29 am IST.

How to invest in Kyverna Therapeutics, Inc. Common Stock Stock (KYTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Kyverna Therapeutics, Inc. Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kyverna Therapeutics, Inc. Common Stock Shares that will get you 0.1572 shares as per Kyverna Therapeutics, Inc. Common Stock share price of $9.54 per share as on April 17, 2026 at 1:29 am IST.

What is the minimum amount required to buy Kyverna Therapeutics, Inc. Common Stock Stock (KYTX) from India?

Indian investors can start investing in Kyverna Therapeutics, Inc. Common Stock (KYTX) shares with as little as ₹93.289 or $1 (as of April 17, 2026 at 2:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹932.89 in Kyverna Therapeutics, Inc. Common Stock stock (as per the Rupee-Dollar exchange rate as on April 17, 2026 at 2:40 pm IST). Based on Kyverna Therapeutics, Inc. Common Stock share’s latest price of $9.54 as on April 17, 2026 at 1:29 am IST, you will get 1.0482 shares of Kyverna Therapeutics, Inc. Common Stock. Learn more about fractional shares .